SynAct Pharma AB (STO:SYNACT)
Sweden · Delayed Price · Currency is SEK 24.20
+1.15 (4.99%)
Oct 31, 2025, 12:59 PM CET
SynAct Pharma AB Company Description
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden.
The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency.
It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.
SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
SynAct Pharma AB
| Country | Sweden |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Jeppe Ovlesen |
Contact Details
Address: ScheelevAegen 2 Lund, 223 63 Sweden | |
| Phone | 46 1 03 00 10 23 |
| Website | synactpharma.com |
Stock Details
| Ticker Symbol | SYNACT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0008241491 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeppe Ovli Ovlesen EE, MBA | Chief Executive Officer |
| Bjorn Westberg | Chief Financial Officer |
| Dr. Thomas Boesen Ph.D. | Chief Operating Officer |
| Kristen Harting M.D. | Chief Medical Officer |
| Mads Bjerregaard | Chief Business Officer |